| [1] |
赫捷,赵平,陈万青.中国肿瘤登记年报[M].北京:军事医学科学出版社,2012:26.
|
| [2] |
Ismail-Khan R, Bui MM.A review of triple-negative breast cancer[J].Cancer Control,2010,17(3):173-176.
|
| [3] |
Yao-Lung K, Dar-Ren C, Tsai-Wang C.Clinicopathological features of triple-negative breast cancer in Taiwanese women[J].Int J Clin Oncol,2011,16(5):500-505.
|
| [4] |
Blows FM, Driver KE,Schmidt MK,et al.Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies[J].PLoS Med,2010,7(5):e1000279.
|
| [5] |
Heitz F, Harter P, Lueck HJ, et al.Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases[J].Eur J Cancer,2009,45(16):2792-2798.
|
| [6] |
Perou CM, Sørlie T, Eisen MB, et al.Molecular portraits of human breast tumours[J].Nature,2000,406(6797):3108-3114.
|
| [7] |
Oakman C, Viale G, Leo AD, et al.Management of triple negative breast cancer[J].Breast,2010,19(5):312-321.
|
| [8] |
Lehmann BD,Bauer JA, Chen X, et al.Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies[J].J Clin Invest,2011,121(7):2750-2767.
|
| [9] |
Prat A, Adamo B, Cheang MC, et al.Molecular characterization of basal-like and non-basal-like triple-negative breast cancer[J].Oncologist,2013,18(2):123-133.
|
| [10] |
Lee DS, Kim SH, Suh YJ, et al.Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy[J].Jpn J Clin Oncol,2011,41(7):854-866.
|
| [11] |
Chae BJ, Bae JS, Lee A, et al.p53 as a specific prognostic factor in triple-negative breast cancer[J].Jpn J Clin Oncol,2009,39(4):217-224.
|
| [12] |
Biganzoli E, Coradini D, Ambrogi F, et al.p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features[J].Jpn J Clin Oncol,2011,41(2):172-179.
|
| [13] |
Kim HS, Yom CK, Kim HJ, et al.Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy[J].Breast Cancer Res Treat,2010,121(3):777-788.
|
| [14] |
Liang Y, Besch-Williford C, Benakanakere I, et al.Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors[J].Breast Cancer Res Treat,2011,125(2):407-420.
|
| [15] |
Jung SY, Han W, Lee JW, et al.Ki-67 expression gives additional prognostic information on St.Gallen 2007 and Adjuvant! Online risk categories in early breast cancer[J].Ann Surg Oncol,2009,16(5):1112-1121.
|
| [16] |
Delpech Y, Wu Y, Hess KR, et al.Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptorpositive metastatic breast cancer[J].Breast Cancer Res Treat,2012,135(2):619-627.
|
| [17] |
Kashiwagi S, Yashiro M, Takashima T, et al.Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage Ⅱ: usefulness of prognostic markers E-cadherin and Ki67[J].Breast Cancer Res,2011,13(6):R122.
|
| [18] |
Niikura N, Iwamoto T, Masuda S, et al.Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer[J].Cancer Sci,2012,103(8):1508-1512.
|
| [19] |
Goldhirsch A, Wood WC, Coates AS.Strategies for subtypesdealing with the diversity of breast cancer: highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol, 2011,22(8):1736-1747.
|
| [20] |
Fasching PA, Heusinger K, Haeberle L, et al.Ki67,chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment[J].BMC Cancer,2011,11:486.
|
| [21] |
Tanei T,Shimomura A,Shimazu K,et al.Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer[J].Eur J Surg Oncol,2011,37(2):155-161.
|
| [22] |
Klintman M, Bendahl PO, Grabau D, et al.The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer[J].Mod Pathol,2010,23(2):251-259.
|
| [23] |
Ishihara M,Mukai H,Nagai S,et al.Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer:effects of biologic subtype and Ki67 overexpression on survival[J].Oncology,2013,84(3):135-140.
|
| [24] |
Rahmanzadeh R, Rai P, Celli JP, et al.Ki-67 as a molecular target for therapy in an in vitro three-dimensional model for ovarian cancer[J].Cancer Res,2010,70(22):9234-9242.
|
| [25] |
Gucalp A, Traina TA.Triple-negative breast cancer: role of the androgen receptor[J].Cancer J,2010,16(1):62-65.
|
| [26] |
Gonzalez-Angulo AM,Stemke-Hale K,Palla SL,et al.Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer [J].Clin Cancer Res, 2009,15(7):2472-2478.
|
| [27] |
He J, Peng R, Yuan Z, et al.Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray[J].Med Oncol,2012,29(2):406-410.
|
| [28] |
Albeck JG, Brugge JS.Uncovering a tumor suppressor for triple-negative breast cancers[J].Cell,2011,144(5):638-640.
|
| [29] |
Possemato R, Marks KM, Shaul YD, et al.Functional genomics reveal that the serine synthesis pathway is essential in breast cancer[J].Nature,2011,476(7360):346-350.
|
| [30] |
Anders CK, Carey LA.Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer[J].Clin Breast Cancer,2009,9 Suppl 2:S73-81.
|
| [31] |
Rakha EA,El-Sayed ME,Green AR,et al.Prognostic markers in triple-negative breast cancer[J].Cancer, 2007,109(1):25-32.
|
| [32] |
Rakha EA, Elsheikh SE, Aleskandarany MA, et al.Triplenegative breast cancer: distinguishing between basal and nonbasal subtypes[J].Clin Cancer Res,2009,15(7):2302-2310.
|
| [33] |
Haffty BG, Yang Q, Reiss M, et al.Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer[J].J Clin Oncol, 2006,24(36):5652-5657.
|
| [34] |
Silver DP, Richardson AL, Eklund AC, et al.Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer[J].J Clin Oncol,2010,28(7):1145-1153.
|
| [35] |
Vollebergh MA, Lips EH, Nederlof PM, et al.An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients[J].Ann Oncol,2011,22(7):1561-1570.
|
| [36] |
Iglehart JD, Silver DP.Synthetic lethality-a new direction in cancer-drug development[J].N Engl J Med,2009, 361(2):189-191.
|
| [37] |
Kwei KA, Kung Y, Salari K, et al.Genomic instability in breast cancer: pathogenesis and clinical implications[J].Mol Oncol,2010,4(3):255-266.
|
| [38] |
Hastak K, Alli E, Ford JM.Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly (ADP-Ribose)polymerase inhibition, gemcitabine, and cisplatin[J].Cancer Res,2010,70(20):7970-7980.
|
| [39] |
O'Shaughnessy J,Schwartzberg LS,Danso MA.A randomized phase Ⅲstudy of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC) [EB/OL].[2013-08-24].http:/ /meetinglibrary.asco.org/content/78038-78102.
|
| [40] |
Gelmon K, Dent R, Mackey JR, et al.Targeting triplenegative breast cancer: optimising therapeutic outcomes[J].Ann Oncol,2012,23(9):2223-2234.
|
| [41] |
Corkery B, Crown J, Clynes M, et al.Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer[J].Ann Oncol,2009,20(5):862-867.
|
| [42] |
Carey LA, Rugo HS, Marcom PK, et al.TBCRC 001:randomized phase Ⅱstudy of cetuximab in combination with carboplatin in stage Ⅳtriple-negative breast cancer[J].J Clin Oncol,2012,30(21):2615-2623.
|
| [43] |
Yotsumoto F, Oki E, Tokunaga E, et al.HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumabresistant breast cancer[J].Int J Cancer, 2010,127(11):2707-2717.
|
| [44] |
Andre F,Job B,Dessen P, et al.Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array[J].Clin Cancer Res, 2009,15(2):441-451.
|
| [45] |
Linderholm BK, Hellborg H, Johansson U, et al.Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triplenegative breast cancer[J].Ann Oncol,2009,20(10):1639-1946.
|
| [46] |
王瑞才,李湘渊,张居民,等.MMP-13、VEGF 在三阴性乳腺癌中的表达及其临床意义[J].中国现代医学杂志, 2010,20(6):872-875.
|
| [47] |
Miller K, Wang M, Gralow J, et al.Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer[J].N Engl J Med,2007,357(26):2666-2676.
|
| [48] |
Miles DW, Chan A, Dirix LY, et al.Phase Ⅲ study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer[J].J Clin Oncol,2010,28(20):3239-3247.
|
| [49] |
Robert NJ, Dieras V, Glaspy J, et al.RIBBON-1:randomized, double-blind, placebo-controlled, phase Ⅲtrial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative,locally recurrent or metastatic breast cancer[J].J Clin Oncol,2011,29(10):1252-1260.
|
| [50] |
O'Shaughnessy J, Miles D, Gray RJ, et al.A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC) [J].J Clin Oncol,2010,28(15S):1005.
|
| [51] |
FDA.Proposal to withdraw approval for the breast cancer indication for AVASTIN((bevacizumab)[EB/OL].[2013-05-20 ].http:/ /www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm279485.htm.
|
| [52] |
Anders CK, Cary LA.Emerging therapies for triple-negative breast cancer[J].Breast Cancer,2013,2(1):47-55.
|
| [53] |
von Minckwitz G, Eidtmann H, Rezai M, et al.Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer[J].N Engl J Med,2012,366(4):299-309.
|
| [54] |
Bear HD, Tang G, Rastogi P, et al.The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40[J].J Clin Oncol,2011,29(18S):1005.
|
| [55] |
Saal LH, Holm K, Maurer M, et al.PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma[J].Cancer Res,2005,65(7):2554-2559.
|
| [56] |
Tryfonopoulos D, Walsh S, Collins DM, et al.Src: a potential target for the treatment of triple-negative breast cancer[J].Ann Oncol,2011,22(10):2234-2240.
|